Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data
PARPIsimprove survival in mCRPC patients with BRCA1/2 mutation, but have no effect in those with ATM mutation. Comparing with PARPIs monotherapy, the combination regimen provides greater survival benefit in the overall population. Future investigation should validate these findings in real-world settings.
Authors
- Qi Xue
- Uzoamaka Adaobi Okoli (ORCID: https://orcid.org/0000-0002-4097-3697)
- Yang Xiong (ORCID: https://orcid.org/0000-0003-3901-2394)
- Fuxun Zhang (ORCID: https://orcid.org/0000-0003-0113-0395)
- Qiang Fu (ORCID: https://orcid.org/0000-0001-7136-5849)
- Geng Zhang (ORCID: https://orcid.org/0000-0001-9038-4316)
- Zhirong Luo (ORCID: https://orcid.org/0009-0006-5399-3482)
- Xuyan Guo
- Yong Jiao (ORCID: https://orcid.org/0009-0009-0248-5885)
- Wei Zhang (ORCID: https://orcid.org/0009-0004-4280-7563)
- Pati-Alam Alisha
Institutions
- University of Nigeria (NG)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Tang Du Hospital (CN)
- University College London (GB)
- Air Force Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-09-19
- DOI
- https://doi.org/10.1097/js9.0000000000003338
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05